FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF	CHANGES	IN	<b>BENEFICIAL</b>	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Rajangam Kanya				2. Issuer Name and Ticker or Trading Symbol Senti Biosciences, Inc. [ SNTI ]						(Ch	eck all application	,		on(s) to Issue 10% Ow Other (sp	ner	
(Last) (First) (Middle) C/O SENTI BIOSCIENCES, INC.			3. Date of Earliest Transaction (Month/Day/Year) 02/01/2023					$\dashv$	below)		below)	, I				
2 CORPORATE DRIVE FIRST FLOOR																
(Street) SOUTH SAN FRANCISCO CA 94080		4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. I Lin	dividual or Joint/Group Filing (Check Applicable )  X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)  2. Trans: Date (Month/I			е	2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.			ed (A) or tr. 3, 4 and	Beneficia Owned Fo	s Form ally (D) o ollowing (I) (Ir		n: Direct I or Indirect I ostr. 4)	7. Nature of ndirect Beneficial Ownership		
							Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	ion(s)			(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)    Conversion or Exercise (Instr. 3)		Transaction   Code (Instr. 8)		Derivative I		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	) (2)		
Stock Option (Right to Buy)	\$1.81	02/01/2023		A		130,000		(1)	01/31/2033	Common Stock	130,000	\$0	130,00	0	D	

## **Explanation of Responses:**

1. The shares underlying this option vest in 48 substantially equal monthly installments over four years from February 1, 2023, subject to the reporting person's continued service through the applicable vesting date.

## Remarks:

/s/ Mike Rhee, attorney-in-fact 02/02/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.